General Information of Drug (ID: DMM57CS)

Drug Name
Drug 2849330 Drug Info
Synonyms 2849330
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMM57CS

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MM-141 DM2RJ4D Pancreatic cancer 2C10 Phase 2 [3]
MEHD-7945A DMHOF7T Colorectal cancer 2B91.Z Phase 2 [4]
Seribantumab DMYT470 Colorectal cancer 2B91.Z Phase 2 [5]
CDX-3379 DM5GKYD Squamous cell carcinoma 2B60-2D01 Phase 2 [5]
MM-121 DMDJRU1 Breast cancer 2C60-2C65 Phase 2 [6]
Elisidepsin DMB38KH Psoriasis vulgaris EA90 Phase 2 [7]
Zenocutuzumab DM1FLHH Pancreatic cancer 2C10 Phase 2 [8]
Sym013 DMZM6I2 Epithelial ovarian cancer 2B5D Phase 1/2 [9]
Zenocutuzomab DMMQGPE Solid tumour/cancer 2A00-2F9Z Phase 1/2 [10]
LJM716 DMGTB5N Breast cancer 2C60-2C65 Phase 1/2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Erbb3 tyrosine kinase receptor (Erbb-3) TTDC8N2 ERBB3_HUMAN Not Available [2]

References

1 ClinicalTrials.gov (NCT01966445) Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors. U.S. National Institutes of Health.
2 National Cancer Institute Drug Dictionary (drug id 754219).
3 MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther. 2014 Feb;13(2):410-25.
4 Company report (Biooncology)
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Company report (Merrimack)
7 Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models. Eur J Cancer. 2009 Jul;45(10):1855-64.
8 Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements. Cancer Discov. 2022 May 2;12(5):1233-1247.
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10 Clinical pipeline report, company report or official report of Merus.
11 An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Cancer Res. 2013 Oct 1;73(19):6024-35.